UNITED STATES SECURITIES AND EXCHANGE COMMISSION January 18, 2013

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Interleukin Genetics, Inc.

File No. 001-32715 - CF#29097

Interleukin Genetics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 10-Q filed on November 14, 2012.

Based on representations by Interleukin Genetics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.1 through September 21, 2022

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Mara L. Ransom Assistant Director